Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Acorda Therapeutics, Inc.
(NQ:
ACOR
)
32.40
USD
+0.24 (+0.75%)
Official Closing Price
/ Updated:
8:10 PM EDT, May 21, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Acorda Therapeutics, Inc.
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
December 21, 2012
from
Business Wire News Releases
Acorda Therapeutics to Present at Piper Jaffray 24th Annual Healthcare Conference
November 20, 2012
from
Business Wire News Releases
Acorda Therapeutics to Present at Lazard Capital Markets 9th Annual Healthcare Conference
November 06, 2012
from
Business Wire News Releases
Acorda Therapeutics Reports Third Quarter 2012 Financial Results
October 31, 2012
from
Business Wire News Releases
Acorda Therapeutics Receives Silver Awards from Medical Marketing & Media Magazine for AMPYRA.com Consumer Website and AMPYRA Healthcare Professional Print Campaign
October 30, 2012
from
Business Wire News Releases
Acorda Therapeutics Moves Third Quarter Financial Results Call to Wednesday, October 31, 2012
October 29, 2012
from
Business Wire News Releases
Acorda Therapeutics to Host Conference Call to Discuss Third Quarter 2012 Financial Results on October 30, 2012
October 23, 2012
from
Business Wire News Releases
Acorda Therapeutics Announces Hatch-Waxman Extension of AMPYRA® (dalfampridine) Sustained-Release Formulation Patent
October 16, 2012
from
Business Wire News Releases
El compromiso de Biogen Idec hacia la esclerosis múltiple se verá demostrado mediante la presentación de importantes datos científicos durante la 28 edición de ECTRIMS
October 10, 2012
from
Business Wire Spanish
AMPYRA® Two-Year Safety Data Presented at 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
October 10, 2012
from
Business Wire News Releases
Biogen Idec’s Commitment to MS Demonstrated Through Significant Scientific Data Being Presented at the 28th ECTRIMS
October 10, 2012
from
Business Wire News Releases
Acorda Therapeutics Names Jane Wasman President, International
October 09, 2012
from
Business Wire News Releases
PetSmart Set to Join the S&P 500; Cabela's to Join the S&P MidCap 400 and Acorda Therapeutics to be Added to the S&P SmallCap 600
October 01, 2012
from
PR Newswire
StudioPMG Earns Two More Prestigious Telly Awards
September 21, 2012
Digital Marketing Agency Honored for Excellence in Web Video Category
Read More
from
Marketwired News Releases
Acorda Therapeutics to Present at UBS Global Life Sciences Conference
September 13, 2012
from
Business Wire News Releases
Acorda Therapeutics to Present at Baird and Stifel Nicolaus 2012 Healthcare Conferences
August 29, 2012
from
Business Wire News Releases
Acorda Therapeutics Announces GGF2 Preclinical Data on Treatment of Erectile Dysfunction
August 28, 2012
from
Business Wire News Releases
National Disability Institute and Acorda Therapeutics Launch Free Webinars on Financial Wellness for People with Multiple Sclerosis
August 14, 2012
from
Business Wire News Releases
Acorda Therapeutics Announces Top Line Results of Post-Marketing Commitment Study Exploring 5 mg Dose of Dalfampridine-ER
August 13, 2012
from
Business Wire News Releases
Acorda Therapeutics Reports Second Quarter 2012 Financial Results
July 31, 2012
from
Business Wire News Releases
Acorda Therapeutics to Host Conference Call to Discuss Second Quarter 2012 Financial Results on July 31, 2012
July 24, 2012
from
Business Wire News Releases
Acorda Therapeutics Relocates Corporate Headquarters to Ardsley Park Life Science Campus
July 19, 2012
from
Business Wire News Releases
Acorda Therapeutics to Present at JMP Healthcare Conference
July 05, 2012
from
Business Wire News Releases
Investigation of Acorda Therapeutics, Inc. by Securities Lawyers at Goldfarb LLP Law Firm for Potential Shareholder Claim
June 14, 2012
from
PR Newswire
Acorda Therapeutics to Present at Wells Fargo 2012 Healthcare Conference
June 12, 2012
from
Business Wire News Releases
Acorda Therapeutics Announces Initiation of AMPYRA® Proof-of-Concept Study in Patients with Post-Stroke Deficits
June 12, 2012
from
Business Wire News Releases
Investigation of Acorda Therapeutics, Inc. by Securities Lawyers at Goldfarb LLP Law Firm for Potential Shareholder Claim
June 05, 2012
from
PR Newswire
Robbins Umeda LLP Announces an Investigation of Acorda Therapeutics, Inc.
June 04, 2012
from
Business Wire News Releases
New Research Presented at 4th Collaborative Meeting of CMSC and ACTRIMS Expands Understanding of MS-Related Walking Impairment and Clinical Usage of AMPYRA®
May 31, 2012
from
Business Wire News Releases
Acorda Therapeutics Launches First-Ever Online Talk Show Focusing on Walking Problems in Multiple Sclerosis
May 30, 2012
from
Business Wire News Releases
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here